2022
Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?
Yao L, Jia G, Lu L, Ma W. Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies? Current Oncology 2022, 29: 4902-4913. PMID: 35877249, PMCID: PMC9320700, DOI: 10.3390/curroncol29070389.Peer-Reviewed Original ResearchConceptsNeoadjuvant chemotherapyBreast cancer patientsCancer patientsEfficacy of NACHuman leukocyte antigen-DR isotypeInitiation of therapyTumor-infiltrating lymphocytesBenefits of treatmentTumor-associated macrophagesOncotype DXMolecular testingPatientsDecreased levelsCancer cellsChemotherapyTreatmentMammaPrintSurgeryLymphocytesTherapyTumorsMacrophages
2020
Surgical approach for interval debulking after neoadjuvant chemotherapy for treatment of advanced ovarian cancer: A single-institution retrospective cohort study
Webster E, Dugan K, McNamara B, Lu L, Azodi M, Ratner E, Schwartz P, Menderes G. Surgical approach for interval debulking after neoadjuvant chemotherapy for treatment of advanced ovarian cancer: A single-institution retrospective cohort study. Gynecologic Oncology 2020, 159: 131. DOI: 10.1016/j.ygyno.2020.05.163.Peer-Reviewed Original Research
2019
Surgical approach for interval debulking after neoadjuvant chemotherapy for treatment of advanced-stage ovarian cancer
Dugan K, McNamara B, Lu L, Litkouhi B, Azodi M, Schwartz P, Ratner E, Menderes G, Silasi D. Surgical approach for interval debulking after neoadjuvant chemotherapy for treatment of advanced-stage ovarian cancer. Gynecologic Oncology 2019, 154: 152. DOI: 10.1016/j.ygyno.2019.04.358.Peer-Reviewed Original Research
2011
Genetic Effects and Modifiers of Radiotherapy and Chemotherapy on Survival in Pancreatic Cancer
Zeng H, Yu H, Lu L, Jain D, Kidd MS, Saif MW, Chanock SJ, Hartge P, Risch H. Genetic Effects and Modifiers of Radiotherapy and Chemotherapy on Survival in Pancreatic Cancer. Pancreas 2011, 40: 657-663. PMID: 21487324, PMCID: PMC3116071, DOI: 10.1097/mpa.0b013e31821268d1.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overATP Binding Cassette Transporter, Subfamily G, Member 2ATP-Binding Cassette TransportersCase-Control StudiesConnecticutDihydrouracil Dehydrogenase (NADP)FemaleGenetic MarkersGenetic VariationGenome-Wide Association StudyHumansMaleMiddle AgedNeoplasm ProteinsPancreatic NeoplasmsPolymorphism, Single NucleotidePrognosisProportional Hazards ModelsSerpinsSurvival AnalysisTreatment OutcomeConceptsPancreatic cancerOverall survivalCancer survivalProportional hazards regression modelsSurvival of patientsPopulation-based studyPancreatic cancer survivalHazards regression modelsGerm-line genetic variationEvidence of associationClinical outcomesCancer patientsTreatment outcomesTreatment responseSignificant associationPatientsCancerPrevious genome-wide association study dataRadiotherapyPutative markerGenetic polymorphismsSurvivalDPYD geneChemotherapyEvidence of interaction